Summit Therapeutics insider buy: 26,680 shares at $18.74

Rhea-AI Filing Summary

Summit Therapeutics (SMMT) insider transaction: Chief Accounting Officer Bhaskar Anand reported acquiring 26,680 shares of common stock at $18.74 per share on 10/21/2025. The shares were acquired in a private placement under a definitive agreement dated October 21, 2025, with the transaction anticipated to close on or about October 23, 2025.

Following the reported transaction, Anand beneficially owned 159,751 shares directly. Holdings include shares previously acquired through the company’s employee stock purchase plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Anand Bhaskar

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	26,680	$18.74	$500K

Holdings After Transaction: Common Stock — 159,751 shares (Direct)

Footnotes (1)

1. Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. Holdings include shares previously acquired through exempt transactions pursuant to the Issuer's employee stock purchase plan.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anand Bhaskar

(Last) (First) (Middle)

C/O SUMMIT THERAPEUTICS INC.

601 BRICKELL KEY DRIVE, SUITE 1000

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/21/2025		A		26,680(1)	A	$18.74	159,751(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.

2. Holdings include shares previously acquired through exempt transactions pursuant to the Issuer's employee stock purchase plan.

Remarks:

	/s/ Bhaskar Anand	10/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SMMT's latest Form 4 disclose?

The Chief Accounting Officer, Bhaskar Anand, acquired 26,680 shares at $18.74 per share on 10/21/2025 in a private placement.

Who was the reporting person in SMMT's Form 4?

The reporting person was Bhaskar Anand, Summit Therapeutics’ Chief Accounting Officer.

How many SMMT shares did the insider acquire and at what price?

He acquired 26,680 shares at a price of $18.74 per share.

What are the insider’s total holdings after the transaction?

Beneficial ownership after the transaction is 159,751 shares, held directly.

What was the nature of the transaction reported by SMMT?

It was a private placement pursuant to a definitive agreement dated October 21, 2025.

When is the private placement expected to close for SMMT?

The transaction is anticipated to close on or about October 23, 2025.

Do the reported holdings include shares from employee plans?

Yes. The holdings include shares previously acquired through the employee stock purchase plan.